γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明，活化的γδ T细胞可能是SCLC治疗的有价值靶点。
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
WT1 树突状细胞疫苗治疗改善终末期肺癌的免疫特征并延长无进展生存期
英文原题：WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer.
研究概要
这些发现表明WT1-DC改善了免疫特征，这可能有助于化疗的持久和持续效果。
中文摘要
WT1 脉冲树突状细胞（WT1-DC）疗法用于治疗在完成卡铂和紫杉醇治疗后不久迅速恶化的终末期鳞状细胞肺癌。随着 WT1-DC 的启动，观察到免疫谱的快速改善。在 WT1-DC 期间，多西他赛和雷莫芦单抗作为二线药物开始使用。免疫谱状态的改善持续存在，同时癌症显示出显著的缩小。无进展生存期超过 577 天，患者能够以 1 的体能状态过上正常的日常生活。这些发现表明，WT1-DC 改善了免疫谱，这可能有助于化疗的持久和持续效果。
展开英文摘要原文
WT1-pulsed dendritic cell (WT1-DC) therapy was performed for end-stage squamous cell lung cancer that rapidly worsened soon after completion of carboplatin and paclitaxel. A rapid improvement in immune profile was observed with the initiation of WT1-DC. Docetaxel and ramucirumab were initiated as second-line agents during WT1-DC. The improvement of the immune profile status continued, and at the same time, the cancer showed a predominant shrinkage. Progression-free survival was over 577 days, and the patient was able to lead a normal daily life with a performance status of 1. These findings suggest that WT1-DC improves the immune profile, and this may contribute to the long-lasting and sustained effect of chemotherapy.
论文信息
- 作者
- Nagai H、Karube R
- 单位
- Oncology, Ginza Phoenix Clinic, Tokyo, JPN.United States
- 文献类型
- 病例报告
- 期刊
- Cureus2023 Oct
- 原文标识
- PubMed 38022278 · DOI 10.7759/cureus.47320